Central Manchester University Hospitals National Health Service Foundation Trust, Old St Mary's Hospital, Manchester, United Kingdom.
Fertil Steril. 2011 Mar 15;95(4):1410-5. doi: 10.1016/j.fertnstert.2010.08.050. Epub 2010 Oct 6.
To create developmentally competent embryos from failed-to-fertilize oocytes for use in infertility research and human embryonic stem cell derivation.
Attempts to recover developmental potential of failed-to-fertilize oocytes were made by using either parthenogenetic activation or reinsemination by intracytoplasmic sperm injection. Resulting embryos were cultured to various stages up to and including blastocyst, and single embryos exhibiting normal development were analyzed for gene expression by quantitatively profiling representative transcripts.
Hospital-based assisted reproductive technology laboratory and University academic laboratories.
PATIENT(S): One hundred sixty-five couples undergoing assisted fertility treatment.
INTERVENTION(S): Metaphase II stage oocytes were either parthenogenetically activated or reinseminated with donor sperm, then allowed to develop up to and including the blastocyst stage.
MAIN OUTCOME MEASURE(S): Gene expression analysis was performed on oocytes and embryos by quantitative reverse transcriptase-polymerase chain reaction for markers of developmental competence.
RESULT(S): Fertilization occurred in 65% of the activated or reinseminated oocytes, which resulted in a blastocyst formation rate of 8%. Evaluation of a number of developmentally important genes in those embryos exhibiting normal development revealed profile and levels of expression similar to control embryos. One blastocyst from an activated oocyte yielded a novel pluripotent stem cell line indistinguishable from those derived from embryos surplus to infertility treatment.
CONCLUSION(S): Clinically unusable oocytes represent a valuable alternative source of normal human embryos for human infertility and stem cell research without conflicting with patient treatment.
从未能受精的卵母细胞中获得具有发育能力的胚胎,用于不孕研究和人类胚胎干细胞的衍生。
通过孤雌激活或胞质内精子注射再受精尝试恢复未能受精的卵母细胞的发育潜能。将得到的胚胎培养至包括囊胚在内的各个阶段,对表现出正常发育的单个胚胎进行基因表达分析,通过定量分析代表性转录本进行分析。
基于医院的辅助生殖技术实验室和大学学术实验室。
165 对接受辅助生育治疗的夫妇。
将中期 II 期卵母细胞进行孤雌激活或与供体精子再受精,然后允许其发育至包括囊胚阶段。
通过定量逆转录聚合酶链反应对卵母细胞和胚胎进行基因表达分析,以评估发育能力的标记物。
在激活或再受精的卵母细胞中,有 65%发生受精,囊胚形成率为 8%。对表现出正常发育的一些胚胎中发育重要基因的评估表明,其表达谱和水平与对照胚胎相似。从激活的卵母细胞中获得的一个囊胚产生了一种新型的多能干细胞系,与那些从多余的不孕治疗胚胎中衍生的干细胞系无法区分。
临床不可用的卵母细胞是用于人类不孕和干细胞研究的正常人类胚胎的有价值的替代来源,而不会与患者治疗产生冲突。